Cancer Research

The persistence of environmental noise and decoherence remains a primary technical hurdle when transitioning quantum diagnostic models from simulations to physical processors. Florida Atlantic University (FAU) researchers have successfully navigated these complexities to achieve a significant

Transcription factors act as biological switches that, when stuck in the 'on' position, trigger the rapid and unregulated cell division characteristic of malignant tumors. For decades, these pivotal components of cellular machinery have remained largely out of reach for modern pharmacology, leading

Standard retreatment for relapsed hairy cell leukemia often involves cumulative chemotherapy toxicity, prompting the search for alternative therapies that do not carry the risk of graft-versus-host disease. Recent advancements in hematologic oncology have ushered in a new era of precision medicine,

Biological engineers have spent decades searching for a nanoscale Swiss Army knife that can simultaneously alert the immune system and deliver precision-guided payloads to malignant cells without the systemic toxicity typically associated with traditional chemotherapy. The M13 bacteriophage, a

Approximately 20 percent of all breast cancer diagnoses are classified as HER2-positive, a subtype historically associated with aggressive growth and poor clinical outcomes. The landscape of HER2-positive early breast cancer treatment has undergone a significant transformation with the European

Incyte Corporation and Genmab A/S have joined forces to launch a Phase 1/2 clinical trial aimed at transforming the treatment landscape for metastatic colorectal cancer patients with the KRAS G12D mutation. This specific genetic alteration has long served as a formidable barrier in oncology, as it